All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke with Karen Rabin, Texas Children’s Hospital, Houston, US. We asked, Can modified chemotherapy regimens improve outcomes for pediatric patients with Down syndrome and high-risk B-ALL?
Modified chemotherapy for pediatric patients with Down syndrome and high-risk B-ALL
Rabin highlights the poor historical outcomes for patients with Down syndrome, including an increased risk of relapse and treatment-related mortality. The prior Children’s Oncology Group trial AALL0232 (NCT00075725) was terminated due to excessive treatment-related mortality due to sepsis and profound neutropenia.
Rabin then discusses data from the recent AALL1131 trial (NCT02883049) investigating a modified chemotherapy regimen to increase safety and improve outcomes; modifications included changing four-drug to three-drug induction, leucovorin rescue after intrathecal methotrexate, modified intravenous methotrexate during interim maintenance, and enhanced supportive care guidelines.
Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia
Individuals with Down syndrome (DS) are 20 times more vulnerable to developing leukemia. The ALL Hub has previously...
MRD and survival outcomes in patients with Down syndrome and acute lymphoblastic leukemia
Patients with both down syndrome (DS) and acute lymphoblastic leukemia (ALL) are at an increased risk of relapse and treatment related mortality when compared...
Subscribe to get the best content related to ALL delivered to your inbox